Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 5/20 | 0.51 |
| ▸ | TNNI3K | Q59H18 | 5/20 | 0.51 |
| ▸ | RET | P07949 | 1/20 | 0.50 |
| ▸ | KDR | P35968 | 8/20 | 0.49 |
| ▸ | EGFR | P00533 | 8/20 | 0.49 |
| ▸ | SRC | P12931 | 1/20 | 0.49 |
| ▸ | AURKA | O14965 | 1/20 | 0.49 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.49 |
| ▸ | CDK1 | P06493 | 1/20 | 0.48 |
| ▸ | FBP1 | P09467 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4764510 | 0.91 | BRAF (0.53) | BRAFTNNI3KRETKDREGFR | |
| SCHEMBL4764408 | 0.90 | RET (0.52) | BRAFTNNI3KRETKDREGFR | |
| SCHEMBL4764786 | 0.88 | LMNA (0.56) | BRAFTNNI3KEGFRFBP1 | |
| SCHEMBL7492858 | 0.88 | RET (0.54) | BRAFTNNI3KRETKDREGFR | |
| SCHEMBL4770085 | 0.87 | HPGD (0.54) | BRAFTNNI3KRETKDREGFR | |
| SCHEMBL7494933 | 0.87 | EGFR (0.61) | BRAFTNNI3KRETEGFRSRC | |
| SCHEMBL4764543 | 0.86 | EGFR (0.54) | BRAFTNNI3KRETKDREGFR | |
| SCHEMBL7496884 | 0.85 | BRAF (0.53) | BRAFTNNI3KRETKDREGFR | |
| SCHEMBL7491908 | 0.85 | RET (0.51) | BRAFTNNI3KRETKDREGFR | |
| SCHEMBL7497991 | 0.84 | BRAF (0.55) | BRAFTNNI3KRETKDREGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0938486-B1 | SUBSTITUTED PYRROLOPYRIMIDINES AND PROCESSES FOR THEIR PREPARATION | NOVARTIS AG (CH) | 2008-01-16 | — | — | EP | claimed |
| US-6180636-B1 | USED TO INHIBIT THE TYROSINE KINASE ACTIVITY OF THE RECEPTOR FOR THE EPIDERMAL GROWTH FACTOR AND C-ERBB2 KINASE AND CAN BE USED AS ANTITUMOR AGENTS | NOVARTIS AG (CH) | 2001-01-30 | — | — | US | claimed |
| EP-0938486-A1 | SUBSTITUTED PYRROLOPYRIMIDINES AND PROCESSES FOR THEIR PREPARATION | Novartis AG (CH) | 1999-09-01 | — | — | EP | claimed |
| WO-1998007726-A1 | SUBSTITUTED PYRROLOPYRIMIDINES AND PROCESSES FOR THEIR PREPARATION | NOVARTIS AG (CH) | 1998-02-26 | — | — | WO | claimed |
| EP-0938486-B1 | SUBSTITUTED PYRROLOPYRIMIDINES AND PROCESSES FOR THEIR PREPARATION | NOVARTIS AG (CH) | 2008-01-16 | — | — | EP | disclosed |
| US-6180636-B1 | USED TO INHIBIT THE TYROSINE KINASE ACTIVITY OF THE RECEPTOR FOR THE EPIDERMAL GROWTH FACTOR AND C-ERBB2 KINASE AND CAN BE USED AS ANTITUMOR AGENTS | NOVARTIS AG (CH) | 2001-01-30 | — | — | US | disclosed |
| EP-0938486-A1 | SUBSTITUTED PYRROLOPYRIMIDINES AND PROCESSES FOR THEIR PREPARATION | Novartis AG (CH) | 1999-09-01 | — | — | EP | disclosed |
| WO-1998007726-A1 | SUBSTITUTED PYRROLOPYRIMIDINES AND PROCESSES FOR THEIR PREPARATION | NOVARTIS AG (CH) | 1998-02-26 | — | — | WO | disclosed |